PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces Second Quarter 2018 Financial Results
- Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the second quarter
View HTML
Toggle Summary Chimerix to Announce Second Quarter 2018 Financial Results on August 8, 2018
DURHAM, N.C. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Wednesday, August 8, 2018 at 8:30 a.m.
View HTML
Toggle Summary Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus
- CMX521 is Active In Vitro Against All Strains of Norovirus Tested - - Oral Dosing of CMX521 Inhibited Norovirus Replication in Animal Model - DURHAM, N.C. , June 12, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical
View HTML
Toggle Summary Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox
DURHAM, N.C. , June 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation for brincidofovir for the treatment
View HTML
Toggle Summary Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)
DURHAM, N.C. , June 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey , MD, MPH will deliver remarks before the House Committee on
View HTML
Toggle Summary Chimerix Announces First Quarter 2018 Financial Results
- Landmark AdVance Study Demonstrates Strong Correlation Between  Adenovirus Burden and Mortality Risk - - Site Initiations for AdAPT Study of Oral Short-course Brincidofovir for Adenovirus and IV Brincidofovir Programs Are Progressing – - First Presentation on CMX521 for Norovirus in June- -
View HTML
Toggle Summary Chimerix to Present at the Deutsche Bank 43rd Annual Health Care Conference
DURHAM, N.C. , May 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will
View HTML
Toggle Summary Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018
DURHAM, N.C. , April 30, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, May 7, 2018 at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference
DURHAM, N.C. , April 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols , M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C.
View HTML
Toggle Summary Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors
DURHAM, N.C. , March 29, 2018 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the appointment of Martha J. Demski as Chair of the Board of Directors. Martha will succeed Ernest Mario , PhD, who is
View HTML